Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

49
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
49
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

30
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
30
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. セプシス誘発性心筋病症:メカニズム,流行,評価,予後,管理

セプシス誘発性心筋病症:メカニズム,流行,評価,予後,管理

Ryota Sato1, Filippo Sanfilippo2, Michael Lanspa3

  • 1Division of Critical Care Medicine, Department of Medicine, The Queen's Medical Center, Honolulu, HI, USA.

Chest
|September 5, 2025

関連する実験動画

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

55.2K
Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

938
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.1K

PubMed で要約を見る

まとめ
この要約は機械生成です。

セプシス誘発性心筋病 (SICM) は,静脈機能不全や右心室損傷を含む心疾患のスペクトルを示しています. これらのフェノタイプを認識することは,セプシス患者に合わせた管理戦略の鍵です.

科学分野:

  • 心臓病科
  • 集中治療 医療
  • 病理生理学

背景:

  • セプシス誘発性心筋病 (SICM) は,セプシスとセプティックショックに関連した複雑な心血管機能障害である.
  • 伝統的に左心室 (LV) 収縮機能不全として見なされ,SICMはダイアストリック機能不全と右心室 (RV) 損傷を含むより広範なフェノタイプを含む.

研究 の 目的:

  • SICMの現象型,その病理生理学,診断方法,および管理への影響に関する現在の理解をレビューする.
  • 認識されていないSICM現象の予後的意義を強調する.

主な方法:

  • SICMに関する既存の文献の包括的なレビュー.
  • エコーカルディオグラフィの調査結果と心機能の測定結果の分析
  • 異なるSICM現象型に関連した報告された有病率と死亡率の評価

主要な成果:

  • SICMは炎症,ミトコンドリア機能障害,および血液動力学的変化を含む.
  • エコーカルディオグラフィは主要な診断ツールであり,評価を強化する新しい手段があります.
  • 発症率は様々です. 静脈動脈シストリック機能障害 (5~32%) 静脈動脈ダイアストリック機能障害 (20~57%) 静脈動脈損傷 (18~79%) がすべて死亡率増加と関連しています.

関連する実験動画

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

55.2K
Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

938
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.1K

結論:

  • SICMは心異常のスペクトルであり, LVの静脈動脈機能障害だけではありません.
  • フェノタイプ認識は患者の管理を最適化するために重要です.
  • 標準化されたプロトコルよりも,個別化され,フェノタイプによる治療方法が推奨されます.